Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-marketing, Prospective, Open-label, Single-group, Multicentre Clinical Investigation to Evaluate the Effectiveness and Safety of a Medical Device Based on Non-cross-linked Hyaluronic Acid in Concentrations of 0.55% ("Electri") and 1.1%, 1.8%, or 2.2% ("XELA REDERM") (Diaco Biofarmaceutici S.r.l., Italy) for Improving the Aesthetic Appearance of Facial Skin.

NCT06984432 is registered in ClinicalTrials.gov with Institute Hyalual GmbH as lead sponsor.

NCT NCT06984432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06984432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-marketing, Prospective, Open-label, Single-group, Multicentre Clinical Investigation to Evaluate the Effectiveness and Safety of a Medical Device Based on Non-cross-linked Hyaluronic Acid in Concentrations of 0.55% ("Electri") and 1.1%, 1.8%, or 2.2% ("XELA REDERM") (Diaco Biofarmaceutici S.r.l., Italy) for Improving the Aesthetic Appearance of Facial Skin.
Lead sponsor
Institute Hyalual GmbH
Phase
Not applicable
Overall status
Completed
Start date
March 30, 2021
Completion date
October 29, 2021
Enrollment
77 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

aesthetic, appearance of facial wrinkles, facial skin wrinkles, hydration